Previous close | 39.19 |
Open | 39.88 |
Bid | 40.16 x 300 |
Ask | 40.22 x 300 |
Day's range | 39.10 - 40.21 |
52-week range | 15.44 - 40.21 |
Volume | |
Avg. volume | 1,498,029 |
Market cap | 6.854B |
Beta (5Y monthly) | 1.54 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.86 |
Earnings date | 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 41.58 |
On May 3, 2024, Jack Anders, the Chief Financial Officer of Revolution Medicines Inc (NASDAQ:RVMD), sold 10,000 shares of the company.
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the qua
Simultaneous publication and presentation of RMC-6236 chemical structure, preclinical data and case studies during the “KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology" Session at AACR 2024 in San DiegoREDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of a peer-reviewed research p